About Seattle Genetics

Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Our strategy is to advance our portfolio of product candidates in diseases with unmet medical need and significant market potential. We have more than 250 employees and are located in a high-technology campus in Bothell, Washington, a suburb of Seattle.

Clinical Development Programs

  • SGN-35 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody linked to a member of the highly potent class of drugs called auristatins using our proprietary ADC technology. In February 2009, we initiated a pivotal trial of SGN-35 for Hodgkin lymphoma under a Special Protocol Assessment (SPA) with the FDA. We are also conducting a phase I trial evaluating weekly dosing of SGN-35 for Hodgkin lymphoma and other CD30-positive malignancies and plan to initiate a phase II trial for systemic anaplastic large cell lymphoma.
     
  • Dacetuzumab (SGN-40) is a humanized antibody targeted to the CD40 antigen. We are developing dacetuzumab under a worldwide collaboration agreement with Genentech (a wholly-owned member of the Roche Group). We and Genentech are conducting a joint development plan that includes five phase Ib-IIb clinical trials of dacetuzumab in combination with standard regimens for the treatment of non-Hodgkin lymphoma and multiple myeloma.
     
  • Lintuzumab (SGN-33) is a humanized antibody targeted to the CD33 antigen. In February 2009, we completed enrollment in a phase IIb trial of low-dose cytarabine +/- lintuzumab in acute myeloid leukemia (AML). Data from the trial are expected in the first half of 2010. We are also conducting a phase I trial of lintuzumab plus Revlimid (lenalidomide) for patients with advanced MDS.
     
  • SGN-70 is a humanized antibody targeted to the CD70 antigen that we are developing as an investigational therapy for autoimmune disease. We are conducting a phase I clinical trial of SGN-70 to evaluate its safety, tolerability and pharmacokinetics in healthy volunteers.

Preclinical Programs

  • SGN-75 is an ADC targeting CD70. This product candidate may have application in solid tumors, including renal cell cancer, CD70-positive hematologic malignancies as well as autoimmune disease. We plan to submit an investigational new drug (IND) application in the second half of 2009 for SGN-75 for cancer.

  • SGN-19A is an ADC targeting the CD19 antigen, a pan-B cell marker expressed on many hematologic malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Corporate Collaborations

We have an exclusive worldwide collaboration agreement with Genentech (a wholly-owned member of the Roche Group) to develop and commercialize dacetuzumab. In addition, we have licensed our ADC technology to Genentech, CuraGen, Progenics, Bayer, Daiichi Sankyo, MedImmune, a wholly-owned subsidiary of AstraZeneca, and Millennium: The Takeda Oncology Company. We also have an agreement with Agensys, a wholly-owned subsidiary of Astellas Pharma, to jointly develop up to two ADC products. We have generated more than $75 million to date from ADC technology collaboration activities.

Discovery and Research Activities

Seattle Genetics has internal research programs directed towards evaluating novel tumor antigens and monoclonal antibodies, discovering new classes of cell-killing drugs, researching novel linker systems and genetically engineering antibody-drug linkage sites. In addition to internal discovery efforts, the company has identified and obtained in-licenses for lead agents and drug candidates from external sources including other companies and academic centers.